Glossary · Clinical

Bone graft substitute (BMP / DBM)

Bone graft substitutes are materials used to fill bone voids or augment fusion when autograft supply is limited or donor-site morbidity is a concern; the two most clinically prominent classes are bone morphogenetic proteins (BMP), which are osteoinductive signaling proteins, and demineralized bone matrix (DBM), an allograft-derived product that retains growth factors after the mineral phase is acid-extracted.

Verified May 8, 2026 · 8 sources ↓

Drawn from AetnaStaticBcbsmHiacodePacificsource

Definition

Source · Editorial summary grounded in 8 cited references ↓

Bone morphogenetic proteins (BMP) are naturally occurring osteoinductive proteins that trigger mesenchymal stem cells to differentiate into osteoblasts, initiating new bone formation without requiring the patient's own bone as a scaffold. The commercially available form, recombinant human BMP-2 (rhBMP-2, brand name INFUSE), is delivered on an absorbable collagen sponge carrier. FDA approval covers anterior lumbar interbody fusion (ALIF) and certain lateral approaches, and acute open tibial shaft fractures stabilized with an intramedullary nail within 14 days of injury. Use outside those indications—cervical fusion, ankle fusion, posterolateral spine—is generally considered experimental or investigational by major payers including Aetna and Cigna.

Demineralized bone matrix (DBM) is produced by acid extraction of cadaveric allograft bone, which dissolves the calcium-phosphate mineral phase and leaves behind collagen, residual growth factors, and non-collagenous proteins. The retained growth factors give DBM weak-to-moderate osteoinductive capacity alongside its osteoconductive scaffold role. DBM is supplied in powder, granule, gel, putty, or strip form—brand examples include Grafton, Osteofil, and Magnifuse. Because formulations differ in particle size, residual mineral content, carrier material, and measured growth-factor activity, clinical performance is not uniform across products. DBM is widely accepted as medically necessary for spinal fusions and bone void filling when used per FDA labeling and payer criteria.

Both product classes sit below autologous iliac-crest bone graft (ICBG) on the evidence hierarchy for spinal arthrodesis, but they avoid the donor-site morbidity and supply constraints of ICBG. Payers typically require on-label use, limit the number of graft categories per surgical incident (commonly one osteoconductive plus one osteoinductive allograft), and may apply quantity limits based on the surgeon's documented clinical rationale.

Why it matters

Payer policy bifurcates sharply between BMP and DBM for coverage and reimbursement. BMP (rhBMP-2) carries a narrow on-label footprint: off-label cervical or posterior lumbar use triggers automatic denials from most commercial payers and raises Medicare audit risk because the procedure code combination may fail NCCI edits or be flagged during post-payment review. DBM does not have a dedicated CPT code—it is reported via add-on graft codes (e.g., 20930) bundled with a covered primary spinal fusion code; submitting those add-on codes without a payable primary procedure code results in outright denial. Confusing BMP with DBM in documentation or code selection can mean the difference between a covered service and a write-off, or between routine processing and a payer audit.

Common mistakes

Where people most often go wrong with this concept.

Source · Editorial brief grounded in cited references ↓

Reporting BMP (rhBMP-2) usage for cervical or posterior lumbar fusion without a payer-specific prior authorization, then billing as if it were an on-label ALIF—most commercial payers deny this as investigational.
Submitting add-on graft codes 20930 or 20931 without a covered primary spinal fusion CPT code on the same claim, causing the add-on to deny as unbundled or incomplete.
Documenting 'bone graft' generically in the operative note without specifying BMP vs. DBM vs. autograft; payers and auditors require the exact product category to validate medical necessity and the chosen procedure code.
Assuming one osteoinductive graft and one osteoconductive graft are always approvable together—some payers approve only one graft category per surgical incident and require explicit documentation of why both were medically necessary.
Billing CPT 0707T or 0814T (calcium-phosphate injection codes) for DBM or BMP procedures; those category-III codes apply specifically to injectable calcium-phosphate osteoconductive materials, not to collagen-sponge BMP constructs or demineralized matrix.
Treating DBM as interchangeable with structural allograft for ICD-10-PCS coding; DBM used as a graft extender in spinal fusion maps to a different tissue-substitute character than a structural cadaveric allograft block.

Related codes

Codes commonly involved when this concept appears in practice.

CPT

ICD-10

M43.16

Modifiers

59 Distinct procedural service LT Left side RT Right side

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 8 cited references ↓

01Is BMP (rhBMP-2) covered by Medicare for spinal fusion?

Medicare coverage follows local coverage determinations (LCDs) and payer policy. rhBMP-2 is FDA-approved for anterior lumbar interbody fusion; use outside that labeled indication is generally not covered and exposes claims to post-payment audit. Always confirm applicable LCD and obtain prior authorization where required.

02Does DBM have its own CPT code?

No. Most bone graft substitutes, including DBM, do not have a dedicated CPT or HCPCS code. DBM used in spinal surgery is typically reported via add-on code 20930 (morselized allograft or osteopromotive material placement), which must be billed alongside a covered primary fusion procedure code.

03What is the ICD-10-PCS coding distinction between BMP and structural allograft in spinal fusion?

In ICD-10-PCS, BMP is classified as an allograft and can optionally be reported with substance code 3E0UGB. Structural cadaveric allograft maps to the non-autologous tissue substitute character. DBM used as a graft extender does not independently drive a separate PCS root operation; it is captured within the fusion procedure. Facility-specific guidelines govern whether optional BMP substance coding is reported.

04Can a surgeon use both DBM and BMP in the same procedure?

Clinically, both may be used together, but payer policies frequently limit coverage to one osteoinductive product per surgical incident. BCBS and similar payers require explicit documentation of medical necessity when combining product categories, and some will approve only one graft per category without additional justification.

05What are the audit risks of billing off-label BMP use?

Off-label BMP use—such as in cervical fusion or posterior lumbar fusion without an ALIF approach—is considered investigational by most payers. Billing without prior authorization or outside FDA-labeled indications creates denial risk on initial submission and recoupment risk on post-payment review. Clear operative-note documentation of the approach and product used is the first line of audit defense.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

When Mira detects documentation of a bone graft substitute in an orthopedic or spinal procedure note, it checks for three things before surfacing a code suggestion. 1. PRODUCT CLASS: Did the surgeon document BMP (rhBMP-2 / INFUSE / collagen sponge carrier) or DBM (demineralized matrix / Grafton / putty/gel/powder form)? These map to different add-on code logic. BMP used in an ALIF or lateral lumbar approach with a covered primary fusion code is reportable; BMP in cervical or posterior lumbar approaches should be flagged for prior-authorization review before billing. 2. PRIMARY PROCEDURE PAIRING: Add-on codes 20930 and 20931 require a payable primary spinal fusion CPT on the same claim. Mira will alert if the primary procedure is missing or non-covered, preventing a standalone add-on denial. 3. QUANTITY AND COMBINATION: If the note documents both an osteoconductive and an osteoinductive graft, Mira flags the combination for documentation review—the surgeon should state why both were necessary, because most payer policies cap coverage at one per category without explicit clinical justification. Mira will also surface modifier 59 when a separately identifiable graft harvest (e.g., 20939 for bone marrow aspiration) is performed through a distinct incision on the same date.

See Mira's approach

Related terms

Allograft Clinical

An allograft is bone or soft tissue harvested from a human donor (typically a cadaver) and transplanted into a different patient to support structural repair or fusion. It is distinct from an autograft, which uses tissue from the patient's own body.